Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In recent years, cannabinoid receptors and their endogenous ligands (endocannabinoids) have been identified within the brain. The high density of CB1 cannabinoid receptors within the basal ganglia suggests a potential role for endocannabinoids in the control of voluntary movement and in basal ganglia‐related movement disorders such as Parkinson's disease. However, whether endocannabinoids play a role in regulating motor behavior in health and disease is unknown. Here we report the presence in two regions of the basal ganglia, the globus pallidus and substantia nigra, of the endocannabinoids 2‐arachidonoylglycerol (2AG) and anand‐amide. The levels of the latter compound are —threefold higher than those previously reported in any other brain region. In the reserpine‐treated rat, an animal model of Parkinson's disease, suppression of locomotion is accompanied by a sevenfold increase in the levels of the 2AG in the globus pallidus, but not in the other five brain regions analyzed. Stimulation of locomotion in the reserpine‐treated rat by either of the two selective agonists of D2 and D1 dopamine receptors, quinpirole and R‐(±)‐3‐allyl‐6‐chloro‐7,8‐dihydroxy‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine hydrobromide (Cl‐APB), respectively, results in the reduction of both anandamide and 2AG levels in the globus pallidus. Finally, full restoration of locomotion in the reserpine‐treated rat is obtained by coadministration of quinpirole and the selective antagonist of the cannabinoid CB1 receptor subtype, SR141716A. These findings indicate a link between endocannabinoid signaling in the globus pallidus and symptoms of Parkinson's disease in the reserpine‐treated rat, and suggest that modulation of the endocannabinoid signaling system might prove useful in treating this or other basal ganglia‐related movement disorders.—Di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., Brotchie, J. M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432–1438 (2000)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationA second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Self-citation3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Notwithstanding the above, studies using SR141716 in rat (Di Marzo et al., 2000) and primate models of PD or LID (Meschler et al., 2001; van der Stelt et al., 2005) provided conflicting results.”
BackgroundResultPharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Self-citationBisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039
“…context, there is a growing interest in 2-AG/CB1 signaling in terms of therapies for a range of conditions including neurodegenerative diseases (Di Marzo et al., 2000; Panikashvili et al., 2001), obesity (Di Marzo et al., 2001), and the extinction of aversive memories (Marsicano et al., 2002).”
BackgroundSelf-citationCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Self-citationTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Self-citationEndocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
Cannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Melis, M., Pistis, M., Perra, S., Muntoni, A. L., Pillolla, G., & Gessa, G. L. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4503-03.2004 · Cited by 478
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 393
Self-citationBiochemistry and pharmacology of endovanilloids
Starowicz, K., Nigam, S., & Di Marzo, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.005 · Cited by 383
Self-citationBISOGNO, T., MELCK, D., BOBROV, M. Y., GRETSKAYA, N. M., BEZUGLOV, V. V., De PETROCELLIS, L., & Di MARZO, V. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510817 · Cited by 381
Self-citationEndocannabinoids control spasticity in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0399fje · Cited by 378
Self-citationIannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Self-citationSUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
Sugiura, T., Kobayashi, Y., Oka, S., & Waku, K. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0356 · Cited by 348
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough
Lang, A. E., & Obeso, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00740-9 · Cited by 345
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agrò, A., & Maccarrone, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-06900.2002 · Cited by 321
Endocannabinoids: synthesis and degradation
Di Marzo, V. (2006) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/112_0505 · Cited by 311
Self-citationPatel, S., Roelke, C. T., Rademacher, D. J., & Hillard, C. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03916.x · Cited by 297
“These findings also support the differential regulation of AEA and 2-AG in vivo and indicate that neuronal activity as measured by the induction of Fos protein is not consistently associated with increased in eCB content (Di Marzo et al., 2000a; Patel et al., 2003a; Valenti et al., 2004).”
BackgroundAnandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum
Maccarrone, M., Rossi, S., Bari, M., De Chiara, V., Fezza, F., Musella, A., Gasperi, V., Prosperetti, C., Bernardi, G., Finazzi-Agrò, A., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2042 · Cited by 295
Hermann, H., Marsicano, G., & Lutz, B. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00509-7 · Cited by 290
van der Stelt, M., & Di Marzo, V. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 291
Self-citationCannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000140288.48796.8e · Cited by 286
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Marinelli, S., Di Marzo, V., Berretta, N., Matias, I., Maccarrone, M., Bernardi, G., & Mercuri, N. B. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03136.2003 · Cited by 258
Self-citationGlobus pallidus external segment
Kita, H. (2007) · Progress in brain research · doi:10.1016/s0079-6123(06)60007-1 · Cited by 228
Centonze, D., Bari, M., Rossi, S., Prosperetti, C., Furlan, R., Fezza, F., De Chiara, V., Battistini, L., Bernardi, G., Bernardini, S., et al. (2007) · Brain · doi:10.1093/brain/awm160 · Cited by 207
Fatty Acid Amide Hydrolase: A Gate-Keeper of the Endocannabinoid System
Fezza, F., De Simone, C., Amadio, D., & Maccarrone, M. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_4 · Cited by 99
Berding, G., Müller-Vahl, K., Schneider, U., Gielow, P., Fitschen, J., Stuhrmann, M., Harke, H., Buchert, R., Donnerstag, F., Hofmann, M., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.005 · Cited by 54
Metadata
- Authors
- di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2000-07
- Volume
- 14
- Issue
- 10
- Pages
- 1432-1438
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W4247729308
- Cited by
- 303
- References
- 30
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.